Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of
Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A)
with a biomarker enrichment stage (Part B) if efficacy is shown in part A.